Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Raw Materials: 2022-2025

Historic Raw Materials for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $6.1 million.

  • Arcutis Biotherapeutics' Raw Materials rose 49.62% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 49.62%. This contributed to the annual value of $4.3 million for FY2024, which is 56.79% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Raw Materials stood at $6.1 million for Q3 2025, which was down 9.01% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Raw Materials ranged from a high of $11.2 million in Q3 2023 and a low of $3.5 million during Q3 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Raw Materials value was $6.7 million (recorded in 2025), while the average stood at $7.2 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Raw Materials skyrocketed by 220.64% in 2023 and then tumbled by 63.49% in 2024.
  • Arcutis Biotherapeutics' Raw Materials (Quarterly) stood at $5.7 million in 2022, then spiked by 75.84% to $10.0 million in 2023, then plummeted by 56.79% to $4.3 million in 2024, then surged by 49.62% to $6.1 million in 2025.
  • Its Raw Materials stands at $6.1 million for Q3 2025, versus $6.7 million for Q2 2025 and $7.6 million for Q1 2025.